The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy.
Paolo A. Zucali
No relevant relationships to disclose
Tommaso Martino De Pas
No relevant relationships to disclose
Giovannella Palmieri
No relevant relationships to disclose
Adolfo G. Favaretto
No relevant relationships to disclose
Antonio Chella
No relevant relationships to disclose
Marcello Tiseo
No relevant relationships to disclose
Michele Caruso
No relevant relationships to disclose
Matteo Perrino
No relevant relationships to disclose
Fabio De Vincenzo
No relevant relationships to disclose
Matteo Simonelli
No relevant relationships to disclose
Francesca Toffalorio
No relevant relationships to disclose
Piera Federico
No relevant relationships to disclose
Giulia Pasello
No relevant relationships to disclose
Marco Ali
No relevant relationships to disclose
Laura Giordano
No relevant relationships to disclose
Monica Bertossi
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose